NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
Mayo Clinic
National Cancer Institute (NCI)
City of Hope Medical Center
University of Washington
Emory University